Safety and Efficacy of ALRV5XR in Women with Androgenetic Alopecia or Telogen Effluvium: A Randomised, Double-Blinded, Placebo-Controlled Clinical Trial
June 2021
in “
EClinicalMedicine
”
Studysummary In this study, ALRV5XR significantly increased hair regrowth in women with androgenetic alopecia or telogen effluvium, with no adverse events reported.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on thelancet.com →